NYSCF Scientific Discovery Biobank

NCT ID: NCT06203106

Last Updated: 2025-03-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-10

Study Completion Date

2045-11-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use.

Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Researchers at the New York Stem Cell Foundation (NYSCF) Research Institute study diverse diseases, conditions, and traits by creating stem cells from biological samples. These "pluripotent" stem cells can become any cell in the human body, including cells that may be difficult, invasive, or impossible to obtain directly.

Additionally, researchers perform genetic testing to learn more about DNA, a material in most cells that contains instructions for the body's development and functions (such as traits like eye color and risk of certain diseases). A piece of DNA that determines the specific role of a cell is called a "gene." If the instructions in a gene are abnormal, this can lead to disease.

Participation in the study involves: (1) completion of health questionnaires, (2) providing a skin and/or blood sample from which stem cells may be created, (3) collection of a saliva sample for genetic analysis, and (4) possible future followup to provide additional information or learn about other research studies.

This study is not a clinical trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ALS Amyotrophic Lateral Sclerosis Alzheimer Disease Alzheimer Disease, Early Onset Alzheimer Disease, Late Onset Batten Disease Corticobasal Degeneration Dementia Frontotemporal Dementia Huntington Disease Lewy Body Disease Multiple Sclerosis Multiple System Atrophy Parkinson Disease Parkinson's Disease and Parkinsonism Progressive Supranuclear Palsy INAD Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1 Macular Degeneration Ovarian Cancer Cervical Cancer Uterine Cancer Vaginal Cancer Vulvar Cancer PTSD Post Traumatic Stress Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Affected Subjects

Subjects in this group will have a diagnosis and/or medical history of a condition, disease, genetic background, or trait of interest.

Biological Sample Collection

Intervention Type OTHER

Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).

Healthy Control

Subjects in this group will serve as healthy controls.

Biological Sample Collection

Intervention Type OTHER

Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biological Sample Collection

Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 30 days or older.
* Diagnosis and/or medical history of a condition, disease, genetic background, or trait of interest or healthy control.
* Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing.
* Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD/ADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and/or Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent.
* Minors undergoing skin collection for research purposes must have a condition, disease, genetic background, or trait of interest and parental/guardian consent.
* Minors undergoing blood, and/or saliva collection for research purposes may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent/guardian to provide consent.
* Minors transferring biological samples and associated data from a procedure outside of the research may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent/guardian to provide consent.

Exclusion Criteria

* Wards of the state.
* For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic.
* For prospective blood samples: history of coagulation disorder.
* For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.
Minimum Eligible Age

30 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

New York Stem Cell Foundation Research Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Laura Andres-Martin, PhD

Role: PRINCIPAL_INVESTIGATOR

New York Stem Cell Foundation Research Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

New York Stem Cell Foundation Research Institute

New York, New York, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Clinical Research Office

Role: CONTACT

212-927-1801

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Clinical Research Office

Role: primary

212-927-1801

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

10-010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MSC Therapy in Liver Transplantation
NCT02260375 RECRUITING PHASE1
Stem Cell Study for Long COVID-19 Neurological Symptoms
NCT06156241 NOT_YET_RECRUITING PHASE1
NEPHSTROM for Diabetic Kidney Disease
NCT02585622 TERMINATED PHASE1/PHASE2